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Objective To evaluate the reliability of theMycobacteria Growth IndicatorTube (MGITAST) for
susceptibility testing ofMycobacterium tuberculosis.
Methods Seventy strains ofM. tuberculosiswere tested for susceptibility to streptomycin, isoniazid,
rifampicin and ethambutol bycomparingMGITASTresults to those obtained by themethod of proportion
(MOP) on Lowenstein^Jensen (LJ) andMiddlebrook 7H10media.The 7H10MOPwas considered the
method of reference.
Results The turnaround time forMGITASTwas 6.2 days (5^10 days) and forMOP it was18^21days.
With rifampicin,MGITASTagreed for all isolates with bothMOP. For streptomycin,MGITASTand 7H10
MOPagreed for 64 isolates (91.4%); 61were susceptible and three resistant. LJMOPand 7H10MOPagreed
for 64 isolates (92.2%); 62 were susceptible and three resistant.With isoniazid, bothMOPagreed for all
isolates, whileMGITASTand 7H10MOPhad two discrepancies. For ethambutol,MGITASTand 7H10
MOPwere concordant for 66 isolates; 65 were susceptible and one resistant. BothMOPwere concordant
for 67 isolates; 66 were susceptible and one resistant.
Conclusions Based on these results, MGITASTis a time-savingmethod and can be used as an alternative
to the BACTECSystem.MGITASTis reliable as far as rifampicin and isoniazid are concerned; however,
additional studies are needed for streptomycin and ethambutol.
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I N T R O D U C T I O N
Tuberculosis (TB) remains a major public health problem in
both developing and developed countries. In Africa, despite
national program facilities, the rate of TB continues to
increase. The lack of accurate methods for diagnosis and the
long delay in providing results are among the main reasons for
this high rate.
Standard methods, methods of proportion onMiddlebrook
7H10 agar and Lowenstein^Jensen (LJ), for determining the
drug susceptibility of Mycobacterium tuberculosis require 3^4
weeks to complete, while patients with resistant organisms
receive treatment with an ine¡ective drug regimen.This delay
may lead to additional drug resistance and failure to control
the disease.
Given the increasing rate of TB, there is a need to develop
more rapid and e¤cient methods for mycobacterial tests (diag-
nosis, susceptibility testing, characterization, etc.).To face this
challenge, experts from the Centers for Disease Control
(CDC) proposed a turnaround time of 30 days from the
receipt of a specimen in the laboratory to complete mycobac-
terial tests [1].
Of the commonly used methods, only the BACTEC 460
System can provide results within 30 days [2,3]. Unfortu-
nately, both the cost and the management of radioactive waste
limit the use of the BACTECSystem.
Recently, Becton Dickinson has introduced the Mycobac-
teria Growth Indicator Tube (MGIT), a broth-based non-
ORIGINAL ARTICLE
= 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
Corresponding author and reprint requests: M. Souleymane, Laboratoire de
Bacte¨riologie-Virologie, Faculte¨ de Me¨decine et de Pharmacie, CHU A. Le
Dantec de Dakar, BP 7325 Dakar-Se¨ne¨gal
Tel: 221822 59 19/82164 20
Fax: 221 82164 42
E-mail: virus@sonatel.senet.net
radiometric system, as an alternative to radiometric systems.
MGIT is a 1100mm tube containing a modi¢ed Middleb-
rook 7H9 broth with an oxygen-quenching £uorescent indi-
cator compound embedded in silicone at the bottom.When
the actively growing mycobacteria consume the oxygen dis-
solved in the broth, the indicator £uoresces when exposed to
365-nm UV light from a transilluminator. By adding M.
tuberculosis suspension to a drug-containingMGIT, an antimy-
cobacterial susceptibility test (AST) can be performed by
comparing the growth of the drug-containing MGIT with
that of the growth control (GC) (drug-freeMGIT).Many stu-
dies have reported the ability of MGIT to shorten the time for
both diagnoses and the reporting of susceptibility testing [3^
7].
The purpose of this study was to assess the reliability of
MGITAST as a rapid drug susceptibility testing method in a
developing country where LJ is the commonly used med-
ium.
M A T E R I A L S A N D M E T H O D S
Seventy-one strains of M. tuberculosis isolated from clinical
specimens of individual patient in Aristide Le Dantec Hospital
in Dakar (Senegal) and identi¢ed by conventional biochem-
ical testing [8,9] were tested for drug susceptibility with the
following ¢rst-line drugs: streptomycin, isoniazid, rifampicin
and ethambutol. Susceptibility was performed in MGITAST,
and on LJ and Middlebrook 7H10 agar medium, by the 1%
method of proportion (MOP) as described previously
[8,10,11]. The MOP on Middlebrook 7H10 agar medium was
used as reference method. M. tuberculosis H37Rv (ATCC
27294) and an in-house M. tuberculosis strain resistant to the
four drugs were included each time the susceptibility testing
was performed as quality control (QC) strains and to check for
the reproducibility of themethod.
For inoculum preparation, colonies were scraped from LJ
slants and transferred to a 16100mm sterile glass tube con-
taining 3mL of Middlebrook 7H9 broth and eight glass
beads.Tubes were vigorously agitated on avortex mixer for 3^
2min, and clumps were allowed to settle for 20min. The
supernatant was removed and transferred to another sterile
glass tube, and clumps were again allowed to settle for 15min.
The supernatant from this tube was removed and transferred
to a ¢nal sterile glass tube and adjusted to match the densities
of 1 and 0.5 standard McFarland suspension. MGIT AST
inoculumwas obtained by a 1: 5 dilution made from 0.5 stan-
dard McFarland suspension. Solid media inocula were
obtained by 10ÿ2, 10ÿ3, 10ÿ4 and 10ÿ5 dilutions made from 1
McFarland.
MGITASTwas performed according to the manufacturer's
recommendations. In brief, lyophilized streptomycin, isonia-
zid, rifampicin and ethambutol (BBL MGITAST SIRE kit)
were reconstituted with sterile distilled water, and 0.1mL of
suspensionwas added to the four MGITs to give the following
¢nal concentrations: streptomycin 0.8mg/L, isoniazid 0.1mg/
L, rifampicin 1.0mg/L and ethambutol 3.5mg/L.These drug-
containing MGITs and one drug-free MGIT (GC) were sup-
plemented with 0.5mL of oleic acid^albumin^dextrose^cat-
alase (OADCBBLMGIT) prior to inoculationwith 0.5mL of
the appropriate dilution of test culture and incubated at 37 C
for up to 12 days.To test bacterial contamination, a trypticase^
soy agar blood plate (BBL) was inoculated with 0.5mL of
MGITAST inoculum and incubated for up to 3 days. A £uor-
escent positive control was prepared by removing the broth
and replacing it with 0.4% (w/v) sodium sul¢te solution, and
an uninoculated MGIT, which shows no £uorescence, was
used as negative control.
Susceptibility testing on solid media was performed as
described previously [8^11], Middlebrook 7H10 agar plates
were inoculated with 100 mL and LJ with 200 mL of the inocu-
lum.These mediawere incubated at 37 C in an atmosphere of
6%CO2 for up to 3weeks. Solid mediawere inspected twice-
weekly, beginning on the secondweekof incubation.
MGITs AST were inspected daily, beginning on the third
day after inoculation. Once the MGITGCwas positive (£uor-
esces), the drug-containing MGITs ASTwere interpreted on
the same day or for up to 2 additional days.The organismwas
then considered as resistant when the drug-containing MGIT
ASTwas positive and susceptible when it was negative within
these 2 days.The test was invalidatedwhen theMGITASTGC
did not £uoresce until the twelfth dayof incubation.
The following performance characteristics were calculated
as described previously [2,3,12]: sensitivity (STöability to
detect true resistance), speci¢city (SPöability to detect true
susceptibility), predictive value of sensitivity (PVSöratio of
true susceptibility to total susceptibility), predictive value of
resistance (PVRöratio of true resistance to total resistance)
and e¤ciency (EFöratio between the number of concordant
results and the total number of results). Statistical analyses
were performedwith EPI Infoversion 6.1.
R E S U L T S
Of the 71 isolates tested, results were available for 70; one iso-
late did not show growth up to 12 days. The turnaround time
for drug susceptibility testing for MGIT AST was 6.2 days,
ranging from 5 to 10 days, while those for 7H10 MOP and LJ
MOP were 18 and 21days, respectively.The QC and reprodu-
cibility performedwith control strains gave the same pattern.
As summarized in Tables1 and 2, all three methods agreed
for 61 isolates; 57 were susceptible and four resistant to at least
one drug. MGIT AST agreed with 7H10 for 61 isolates (EF
87.1%); 57 were susceptible and four resistant to at least one
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drug. LJ agreed with 7H10 for 63 isolates (EF 90%); 59 were
susceptible and four resistant to at least one drug.
Streptomycin
The results of the three methods agreed for 64 isolates; 61
were susceptible and three resistant. MGIT AST and 7H10
MOP were concordant for 64 isolates (EF 91.4%); 61 isolates
were susceptible and three resistant. Of the six discrepant iso-
lates, ¢ve were resistant by 7H10 MOP and susceptible by
MGITAST, and one was resistant by MGITASTand suscepti-
ble by 7H10 MOP. LJ and 7H10 MOP were concordant for 65
isolates (EF 92.2%); 62 were susceptible and three resistant.
The ¢ve discrepant isolates were resistant by 7H10 MOP and
susceptible by MOP. No statistically signi¢cant di¡erence was
seen between the two combinations (P 0.62). MGIT AST
versus LJMOPshowed onlyone discrepancy, inwhich the iso-
late was resistant byMGITand susceptible by LJ.
Isoniazid
All three methods agreed for 68 isolates (EF 97.1%); 62 were
susceptible and six resistant. The two discrepant isolates were
resistant by MGITAST and susceptible by 7H10 MOP. Both
MOP agreed for all isolates; 64 were susceptible and six resis-
tant. No statistically signi¢cant di¡erence was observed
betweenMGITASTand LJMOP (P 0.46).
Rifampicin
The results of the three methods agreed for all isolates; 66
were susceptible and four resistant.
Ethambutol
All three methods agreed for 66 isolates; 65 were susceptible
and one resistant. MGIT AST and 7H10 MOP were concor-
dant for 66 isolates (EF 94.2%); 65 were susceptible and one
resistant. Of the four discrepant isolates observed, three were
resistant by 7H10 MOP and susceptible by MGITAST, while
one was resistant by MGIT AST and susceptible by 7H10
MOP. Both MOP were concordant for 67 isolates (95.7%); 66
were susceptible and one resistant.The three discrepant isolates
were resistant by the reference method and susceptible by LJ
MOP (P 0.93). MGITASTversus LJ MOP showed one dis-
crepancy, in which the isolate was resistant by MGITASTand
susceptible by LJMOP.
For the overall discrepancies observed between MGIT
AST/LJMOP and the reference method, most of the discre-
pant isolates were susceptible by MGIT AST/LJ MOP and
resistant by the referencemethod.
Details of these discrepancies are summarized in Tables1
and 2. Overall, in terms of results, MGITASTwas closer to LJ
MOP than to 7H10MOP.
The MGIT AST performance characteristics summarized
inTable 3 show ST, SP, PVR and PVS of 100% for rifampicin,
while those of streptomycin, isoniazid and ethambutol ranged
from 25% to100%.
D I S C U S S I O N
The increase in mycobacterial disease has stimulated the need
to develop more rapid and reliable methods for diagnostic and
susceptibility testing. It is widely known that drug susceptibil-
ity testing of M. tuberculosis is more rapid in liquid medium
Table 1 Analysis of susceptibilities by the three methods
MGIT AST LJ
ATB 7H10 Total S R S R
Streptomycin
S 62 61 1 62 0
R 8 5 3 5 3
Isoniazid
S 64 62 2 64 0
R 6 0 6 0 6
Rifampicin
S 66 66 0 66 0
R 4 0 4 0 4
Ethambutol
S 66 65 1 66 0
R 4 3 1 3 1
Table 2 Analyses of susceptibilities by MGIT AST and LJ MOP
LJ
ATB MGIT AST S R EFa
Streptomycin
S 66 0 98.5
R 1 3 98.5
Isoniazid
S 62 0 97.1
R 2 6 97.1
Rifampicin
S 66 0 100
R 0 4 100
Ethambutol
S 68 0 98.5
R 1 1 98.5
aEf®ciency of MGIT AST compared to LJ MOP as standard method.
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than in solid medium [3,4,13]. Among liquid media used for
susceptibility testing ofM tuberculosis, the BACTEC System is
the only commonly used method in public health, despite its
cost and the radioactive material required.The recently intro-
duced MGITAST has been reported to have good reliability
for susceptibility testing ofM. tuberculosis [4,6].
This study was performed to evaluate the reliability of
MGIT AST as compared to LJ MOP for the ¢rst-line drugs
streptomycin, isoniazid, rifampicin and ethambutol, using
7H10MOPas the reference method.
The turnaround time for MGITAST in this study was 6.2
days, compared to 21days for theMOP. Similar data have been
reported previously [6,7,14]. This short time to complete sus-
ceptibility testing combined with the short time to detection
of M. tuberculosis in clinical specimens reported earlier [3]
could allow laboratories using this medium to reduce the delay
in completing the mycobacteria tests, as suggested by the
CDC [1].
Among the 70 isolates, MGIT AST agreed with 7H10
MOP and LJ MOP for 87.1% and 95.7% of isolates, respec-
tively. Results obtained with MGITAST are divided into the
following groups:
1. Isoniazid and rifampicin with 97.1% and 100% e¤ciency,
respectively. Only two discrepancies were observed between
MGIT AST and the two MOP; the discrepant isolates were
resistant by MGIT AST and susceptible by both MOP. This
excellent agreement con¢rmed ¢ndings reported previously
[4^7,15^16].
2. Streptomycin and ethambutol with 91.4% and 94.2% e¤-
ciency, respectively. There were six and four discrepancies
between MGITASTand 7H10 MOP, respectively, for strepto-
mycin and ethambutol. Similar ¢ndings were reported pre-
viously [5,17]. In this study, and that performed by Gerome
et al [17], most of the discrepant isolates observedwith strepto-
mycin and ethambutol were false positives.The same ¢ndings
were reported by other studies [5,17]. This number of false
positives with streptomycin and ethambutol detected by
MGIT AST seems more likely due to the inability of MGIT
AST to detect low levels of resistance (low proportion of resis-
tant bacilli). In BACTEC 460 this problem was solved by
comparing test vials with a1: 100 diluted GC.
MGITAST performance characteristics were high for iso-
niazid and rifampicin, except for isoniazid PVR. These per-
formance characteristics were similar to those reported earlier
[3,4]. On the other hand, streptomycin and ethambutol
showed low STand PVR, while SP and PVS were high. This
di¡erence in values was due to the number of false negatives
detected byMGITAST. In terms of e¤ciency, when compared
to LJMOP, theMGITASTreached an agreement level of 95%
(97.1^100%). Similar results were observed by Lazlo et al [12]
when comparing BACTEC 460with LJ.
In summary, our data suggest the following conclusions:
(1) in terms of time, MGITAST is a time-saving method and
can be used as an alternative to the BACTEC System to
shorten the delay in reporting the susceptibility results; (2) in
terms of accuracy, MGITAST is a reliable method for the sus-
ceptibility testing of M. tuberculosis complex with rifampicin
and isoniazid and can be used for the rapid screening of multi-
resistant strains. Further studies need to be performed includ-
ing a high number of resistant strains for streptomycin and
ethambutol to better evaluate their sensitivity and PVR. For
all the ¢rst-line drugs, MGITAST can be used in place of LJ
MOPas a susceptibility testingmethod.
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